RWJ-56110 是一种有效的、选择性的拟肽抑制剂,可抑制 PAR-1 激活和内化(结合 IC50=0.44 uM),对 PAR-2、PAR-3 和 PAR-4 无影响,并能抑制由 SFLLRN-NH2(IC50=0.16 μM)和凝血酶(IC50=0.34 μM)诱导的血小板聚集,相对于 U46619 (MS-O09517) 具有相当的选择性,同时在体内阻断血管生成和新血管的形成,并诱导细胞凋亡 (apoptosis)。
产品编号: MS-W82696 CAS No.: 252889-88-6 分子式: C41H43Cl2F2N7O3 分子量: 790.73
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

RWJ-56110 是一种有效的、选择性的拟肽抑制剂,可抑制 PAR-1 激活和内化(结合 IC50=0.44 uM),对 PAR-2、PAR-3 和 PAR-4 无影响,并能抑制由 SFLLRN-NH2(IC50=0.16 μM)和凝血酶(IC50=0.34 μM)诱导的血小板聚集,相对于 U46619 (MS-O09517) 具有相当的选择性,同时在体内阻断血管生成和新血管的形成,并诱导细胞凋亡 (apoptosis)。

生物实验数据

生物活性 RWJ-56110 is a potent and selective peptidomimetic inhibitor that inhibits PAR-1 activation and internalization (binding IC50=0.44 uM) without affecting PAR-2, PAR-3, or PAR-4, inhibits platelet aggregation induced by SFLLRN-NH2 (IC50=0.16 μM) and thrombin (IC50=0.34 μM) with comparable selectivity relative to U46619 (MS-O09517), blocks angiogenesis and neovascularization in vivo, and induces apoptosis.
IC50 & Target PAR1:0.44 uM (IC50), Platelet aggregation (human, thrombin-induced):0.34 μM (IC50), Platelet aggregation (human, SFLLRN-NH2-induced):0.16 μM (IC50)
体外研究
(In Vitro)

Proteinase-activated receptors (PARs) are a family of G protein-coupled receptors activated by the proteolytic cleavage of their N-terminal extracellular domain, exposing a new amino terminal sequence that functions as a tethered ligand to activate the receptors.
RWJ56110 inhibits the aggregation of human platelets induced by both SFLLRN-NH2 (IC50=0.16 μM) and thrombin (IC50=0.34 μM) while being quite selective relative to collagen and the thromboxane mimetic U46619 (MS-O09517).
RWJ-56110 is fully inhibits thrombin-induced RASMC proliferation with an IC50 value of 3.5 μM. RWJ-56110 shows blockade of thrombin’s action with RASMC calcium mobilization (IC50=0.12 μM), as well as with HMVEC (IC50=0.13 μM) and HASMC calcium mobilization (IC50=0.17 μM).
RWJ56110 (0.1-10 μM; 24-96 hours) inhibits endothelial cell growth dose-dependently, with half-maximal inhibitory concentration of RWJ56110 is approximately 10 μM.
RWJ56110 (0.1-10 μM; 6 hours) inhibits DNA synthesis of endothelial cells in a thymidine incorporation assays. Endothelial cells are in fast-growing state (50-60% confluence), RWJ56110 inhibits cell DNA synthesis in a dose-dependent manner, but when cells that are in the quiescent state (100% confluent), the inhibitory effect of PAR-1 antagonists is much less pronounced.
RWJ56110 (0.1-10 μM; pretreatment for 15 min) inhibits thrombin-induced Erk1/2 activation in a concentration-dependent manner. However, when endothelial cells are stimulated by FBS (final concentration 4%), it reduces partially the activated levels of Erk1/2.
RWJ56110 (30 μM; 24 hours) has an inhibitory effect on endothelial cell cycle progression. It reduces the percentage of cells in the S phase, while alterations in the percentages of G1 and G2/M cells are less pronounced.

Western Blot Analysis

Cell Line: Endothelial cells
Concentration: 0 μM; 3 μM; 1 μM; 3 μM; 10 μM
Incubation Time: Pretreatment for 15 min
Result: Resulted in MAPK activation in Endothelial cells.

Cell Cycle Analysis

Cell Line: Endothelial cells
Concentration: 0 μM; 3 μM; 1 μM; 3 μM; 10 μM
Incubation Time: Pretreatment for 15 min
Result: Reduced cell number in S phase.

化学信息

分子量 790.73
分子式 C41H43Cl2F2N7O3
CAS No. 252889-88-6

储存&溶解度

溶解度信息
H2O: <21.59 mg/mL, Sonication is recommended.
DMSO: <86.36 mg/mL, Sonication is recommended.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础